Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $12.20 Consensus PT from Analysts

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has been given a consensus recommendation of "Buy" by the six analysts that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $12.20.

RANI has been the subject of several research reports. BTIG Research raised their price objective on shares of Rani Therapeutics from $7.00 to $14.00 and gave the company a "buy" rating in a research report on Thursday. Wedbush restated an "outperform" rating and set a $8.00 price objective on shares of Rani Therapeutics in a research report on Tuesday, February 6th. Canaccord Genuity Group reduced their price objective on shares of Rani Therapeutics from $21.00 to $9.00 and set a "buy" rating for the company in a research report on Wednesday, March 27th. Finally, HC Wainwright lifted their price objective on Rani Therapeutics from $12.00 to $13.00 and gave the company a "buy" rating in a report on Tuesday.

Rani Therapeutics Price Performance

RANI traded down $0.37 on Thursday, reaching $6.78. The company had a trading volume of 224,351 shares, compared to its average volume of 128,421. The company has a fifty day moving average of $4.73 and a 200-day moving average of $3.53. The company has a market capitalization of $340.08 million, a P/E ratio of -5.10 and a beta of 0.33. The company has a current ratio of 6.36, a quick ratio of 6.36 and a debt-to-equity ratio of 0.96. Rani Therapeutics has a one year low of $1.82 and a one year high of $8.75.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.04. As a group, equities research analysts anticipate that Rani Therapeutics will post -0.94 earnings per share for the current year.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.